Drug helps patients with relapsed myelomaBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7405.7-a (Published 03 July 2003) Cite this as: BMJ 2003;327:7
- Janice Hopkins Tanne
- New York
Bortezomib, the first of a new class of drugs called proteasome inhibitors, produced a 35% response rate in patients with relapsed, refractory multiple myeloma, an unusually high rate in these patients, for whom there is no other treatment.
A phase II study published in the New England Journal of Medicine (2003;348: 2609-17 led the US Food and Drug Administration to grant accelerated approval to Millennium Pharmaceuticals to provide the drug to patients whose disease …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial